Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249777732> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4249777732 endingPage "611" @default.
- W4249777732 startingPage "595" @default.
- W4249777732 abstract "Histone deacetylase (HDAC) inhibitors are amongst the newer therapies being introduced in refractory, relapsed, and resistant disease. These agents are mechanism-based and their use is targeted to the diseased cell or tissue. HDACs are key enzymes in the regulation of gene expression. They maintain a dynamic equilibrium in the acetylation state of highly conserved lysine residues on histones by which they regulate chromatin remodeling and gene expression. Changes in growth and differentiation leading to malignancy appear to occur by alterations in transcriptional control and gene silencing. Histone acetylation and DNA methylation have been implicated in these aberrant phenotypes. Inhibitors of DNA methylation such as 5-azacytidine or 5-azadeoxycytidine have been able to reverse DNA methylation patterns and have shown promise in patient studies. Similarly, HDAC inhibitors block deacetylation function, causing cell cycle arrest, differentiation, and/or apoptosis of many tumors. Several HDAC inhibitors have exhibited potent antitumor activity in human xenograft models, suggesting their usefulness as novel cancer therapeutic agents. Several are currently in phase I/II clinical trials both in hematological malignancies and in solid tumors. Agents used initially, such as phenylbutyrate, are effective in millimolar concentrations. Newer agents are being developed and these are effective at much lower concentrations and are relatively less toxic. In particular, hydroxamic acid-based polar compounds and cyclic tetrapeptides have shown activity against cancers at well-tolerated doses." @default.
- W4249777732 created "2022-05-12" @default.
- W4249777732 creator A5066001318 @default.
- W4249777732 creator A5066379655 @default.
- W4249777732 date "2004-12-01" @default.
- W4249777732 modified "2023-10-17" @default.
- W4249777732 title "Histone deacetylase inhibitors in myelodysplastic syndrome" @default.
- W4249777732 doi "https://doi.org/10.1016/s1521-6926(04)00077-5" @default.
- W4249777732 hasPublicationYear "2004" @default.
- W4249777732 type Work @default.
- W4249777732 citedByCount "11" @default.
- W4249777732 countsByYear W42497777322012 @default.
- W4249777732 countsByYear W42497777322016 @default.
- W4249777732 countsByYear W42497777322017 @default.
- W4249777732 crossrefType "journal-article" @default.
- W4249777732 hasAuthorship W4249777732A5066001318 @default.
- W4249777732 hasAuthorship W4249777732A5066379655 @default.
- W4249777732 hasConcept C104317684 @default.
- W4249777732 hasConcept C114691636 @default.
- W4249777732 hasConcept C119056186 @default.
- W4249777732 hasConcept C119157956 @default.
- W4249777732 hasConcept C134018914 @default.
- W4249777732 hasConcept C150194340 @default.
- W4249777732 hasConcept C150425827 @default.
- W4249777732 hasConcept C167227067 @default.
- W4249777732 hasConcept C190727270 @default.
- W4249777732 hasConcept C27253355 @default.
- W4249777732 hasConcept C2776262904 @default.
- W4249777732 hasConcept C2778305200 @default.
- W4249777732 hasConcept C2909310144 @default.
- W4249777732 hasConcept C41091548 @default.
- W4249777732 hasConcept C4951695 @default.
- W4249777732 hasConcept C502942594 @default.
- W4249777732 hasConcept C55493867 @default.
- W4249777732 hasConcept C64927066 @default.
- W4249777732 hasConcept C71723506 @default.
- W4249777732 hasConcept C83640560 @default.
- W4249777732 hasConcept C86803240 @default.
- W4249777732 hasConceptScore W4249777732C104317684 @default.
- W4249777732 hasConceptScore W4249777732C114691636 @default.
- W4249777732 hasConceptScore W4249777732C119056186 @default.
- W4249777732 hasConceptScore W4249777732C119157956 @default.
- W4249777732 hasConceptScore W4249777732C134018914 @default.
- W4249777732 hasConceptScore W4249777732C150194340 @default.
- W4249777732 hasConceptScore W4249777732C150425827 @default.
- W4249777732 hasConceptScore W4249777732C167227067 @default.
- W4249777732 hasConceptScore W4249777732C190727270 @default.
- W4249777732 hasConceptScore W4249777732C27253355 @default.
- W4249777732 hasConceptScore W4249777732C2776262904 @default.
- W4249777732 hasConceptScore W4249777732C2778305200 @default.
- W4249777732 hasConceptScore W4249777732C2909310144 @default.
- W4249777732 hasConceptScore W4249777732C41091548 @default.
- W4249777732 hasConceptScore W4249777732C4951695 @default.
- W4249777732 hasConceptScore W4249777732C502942594 @default.
- W4249777732 hasConceptScore W4249777732C55493867 @default.
- W4249777732 hasConceptScore W4249777732C64927066 @default.
- W4249777732 hasConceptScore W4249777732C71723506 @default.
- W4249777732 hasConceptScore W4249777732C83640560 @default.
- W4249777732 hasConceptScore W4249777732C86803240 @default.
- W4249777732 hasIssue "4" @default.
- W4249777732 hasLocation W42497777321 @default.
- W4249777732 hasOpenAccess W4249777732 @default.
- W4249777732 hasPrimaryLocation W42497777321 @default.
- W4249777732 hasRelatedWork W1995040570 @default.
- W4249777732 hasRelatedWork W2029788469 @default.
- W4249777732 hasRelatedWork W2075984614 @default.
- W4249777732 hasRelatedWork W2094953745 @default.
- W4249777732 hasRelatedWork W2099440961 @default.
- W4249777732 hasRelatedWork W2142415093 @default.
- W4249777732 hasRelatedWork W2155804574 @default.
- W4249777732 hasRelatedWork W2357266420 @default.
- W4249777732 hasRelatedWork W2552712024 @default.
- W4249777732 hasRelatedWork W4249777732 @default.
- W4249777732 hasVolume "17" @default.
- W4249777732 isParatext "false" @default.
- W4249777732 isRetracted "false" @default.
- W4249777732 workType "article" @default.